Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-6

It was also good to hear that discussions are still being held with potential future partners - let's hope they get some legs!

“We continue to make excellent progress on all fronts,” commented Percheron CEO, Dr James Garner. “Recruitment to the international phase IIb study of ATL1102 in Duchenne muscular dystrophy has accelerated during recent months, and we remain optimistic about completing recruitment in the first quarter of calendar 2024. Alongside the execution of the clinical trial, the team has been carefully reviewing the regulatory dossier for ATL1102 to identify both opportunities and gaps that may be relevant to future regulatory discussions. In addition, the recent JP Morgan Healthcare Conference provided rich opportunities to discuss the program with potential future partners, and we look forward to continuing those discussions over the coming months.”
.